News | 23 October 2023
KKR to invest in life sciences firm Catalio Capital Management
Investment is additive to KKR’s existing health care growth strategy
Investment is additive to KKR’s existing health care growth strategy
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Aarti Drugs has reported total income of Rs. 642.22 crores during the period ended September 30, 2023
Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023
hey were educated about the 7- step hand-washing technique trainings
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
The plant has a capacity for extraction of 2500 mt of poppy straw and 300 mt poppy gum per year
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Lupin enters into BTA with Lupin Manufacturing Solutions
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
The composition of ORAAL is protected by a granted patent in India until November 2033
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Subscribe To Our Newsletter & Stay Updated
